CU20150176A7 - Derivados de prodroga de triazolpiridinas sustituídas - Google Patents

Derivados de prodroga de triazolpiridinas sustituídas

Info

Publication number
CU20150176A7
CU20150176A7 CUP2015000176A CU20150176A CU20150176A7 CU 20150176 A7 CU20150176 A7 CU 20150176A7 CU P2015000176 A CUP2015000176 A CU P2015000176A CU 20150176 A CU20150176 A CU 20150176A CU 20150176 A7 CU20150176 A7 CU 20150176A7
Authority
CU
Cuba
Prior art keywords
derivatives
triazolpiridines
substituted
supply
mps
Prior art date
Application number
CUP2015000176A
Other languages
English (en)
Inventor
Volker Schulze
Hans-Georg Lerchen
Donald Bierer
Antje Margret Wengner
Gerhard Siemeister
Dr Philip Lienau
Ursula Krenz
Dr Dirk Kosemund
Dr Detlef Stöckigt
Dr Michael Brüning
Dr Ulrich Lücking
Ildiko Terebesi
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20150176A7 publication Critical patent/CU20150176A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de prodroga de inhibidores de la quinasa Mps-1, procesos para su preparación y su uso en el tratamiento y/o la profilaxis de enfermedades.
CUP2015000176A 2013-06-11 2015-12-11 Derivados de prodroga de triazolpiridinas sustituídas CU20150176A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171508 2013-06-11
PCT/EP2014/061779 WO2014198647A2 (en) 2013-06-11 2014-06-06 Prodrug derivatives of substituted triazolopyridines

Publications (1)

Publication Number Publication Date
CU20150176A7 true CU20150176A7 (es) 2016-05-30

Family

ID=48576905

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000176A CU20150176A7 (es) 2013-06-11 2015-12-11 Derivados de prodroga de triazolpiridinas sustituídas

Country Status (35)

Country Link
US (1) US9586958B2 (es)
EP (1) EP3008062B1 (es)
JP (1) JP2016526534A (es)
KR (1) KR20160019492A (es)
CN (1) CN105377848A (es)
AP (1) AP2015008898A0 (es)
AR (1) AR096585A1 (es)
AU (1) AU2014280356A1 (es)
CA (1) CA2914745A1 (es)
CL (1) CL2015003605A1 (es)
CR (1) CR20150659A (es)
CU (1) CU20150176A7 (es)
DK (1) DK3008062T3 (es)
DO (1) DOP2015000299A (es)
EA (1) EA201600002A1 (es)
ES (1) ES2626790T3 (es)
HK (1) HK1221955A1 (es)
HR (1) HRP20170717T1 (es)
HU (1) HUE033131T2 (es)
IL (1) IL242847A0 (es)
LT (1) LT3008062T (es)
MA (1) MA38654B1 (es)
MX (1) MX2015017119A (es)
NI (1) NI201500176A (es)
PE (1) PE20160156A1 (es)
PH (1) PH12015502746A1 (es)
PL (1) PL3008062T3 (es)
PT (1) PT3008062T (es)
RS (1) RS56034B1 (es)
SG (1) SG11201509858QA (es)
SI (1) SI3008062T1 (es)
TN (1) TN2015000545A1 (es)
UY (1) UY35610A (es)
WO (1) WO2014198647A2 (es)
ZA (1) ZA201508868B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
PT3283642T (pt) 2015-04-17 2024-01-02 Crossfire Oncology Holding B V Biomarcadores de prognóstico para quimioterapia inibidora de ttk
MX2018011831A (es) 2016-04-04 2019-02-13 Chemocentryx Inc Antagonistas solubles de receptor de c5aa(c5ar).
CA3241111A1 (en) * 2021-12-15 2023-06-22 Heidi Lane Methods of treating neoplastic diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69736711T2 (de) 1996-08-28 2007-09-20 Pfizer Inc. Substituierte 6,5-heterobicyclische-derivate
IL133007A (en) 1997-05-28 2005-06-19 Aventis Pharma Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
EP1799680A2 (en) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
EA200870592A1 (ru) 2006-05-31 2009-08-28 Галапагос Н.В. Триазолопиразиновые соединения, пригодные для лечения дегенеративных и воспалительных заболеваний
US20100075947A1 (en) 2006-08-16 2010-03-25 Exelixis, Inc. Methods of Using PI3K and MEK Modulators
CN103641829A (zh) 2006-08-30 2014-03-19 塞尔佐姆有限公司 作为激酶抑制剂的三唑衍生物
PE20090288A1 (es) 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体
MX2010002115A (es) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
KR20100075881A (ko) 2007-08-31 2010-07-05 메르크 세로노 에스. 에이. 트리아졸로피리딘 화합물 및 ａｓｋ 저해제로서 이의 용도
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2222674B8 (en) 2007-11-27 2016-01-06 Cellzome Limited Amino triazoles as pi3k inhibitors
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
EA201101188A1 (ru) 2009-02-13 2012-04-30 Фовеа Фармасьютикалз [1,2,4]триазоло[1,5-а]пиридины в качестве ингибиторов киназы
CN102413831B (zh) 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
CN102596932A (zh) 2009-09-04 2012-07-18 拜耳医药股份有限公司 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2523949B1 (en) 2010-01-15 2014-08-20 Janssen Pharmaceuticals Inc. Novel substituted triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
AU2012244859B2 (en) 2011-04-21 2017-06-08 Bayer Intellectual Property Gmbh Triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
ES2605946T3 (es) 2012-03-14 2017-03-17 Bayer Intellectual Property Gmbh Imidazopiridazinas sustituidas
EP2872506A1 (en) * 2012-07-10 2015-05-20 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
CN105431435A (zh) * 2013-06-07 2016-03-23 拜耳制药股份公司 具有作为mps-1抑制剂的活性的取代的三唑并吡啶类
BR112015030774A2 (pt) * 2013-06-10 2017-07-25 Bayer Pharma AG novos compostos para o tratamento de câncer
CA2914742A1 (en) * 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Handovers with co-operating cells configured to provide coordinated multi-point transmission/reception

Also Published As

Publication number Publication date
HK1221955A1 (zh) 2017-06-16
ZA201508868B (en) 2017-08-30
EP3008062A2 (en) 2016-04-20
SG11201509858QA (en) 2015-12-30
CL2015003605A1 (es) 2016-06-24
WO2014198647A2 (en) 2014-12-18
CA2914745A1 (en) 2014-12-18
RS56034B1 (sr) 2017-09-29
ES2626790T3 (es) 2017-07-26
TN2015000545A1 (en) 2017-04-06
US20160207915A1 (en) 2016-07-21
DK3008062T3 (en) 2017-06-12
EA201600002A1 (ru) 2016-06-30
WO2014198647A3 (en) 2015-02-05
LT3008062T (lt) 2017-06-12
NI201500176A (es) 2016-01-06
AR096585A1 (es) 2016-01-20
CR20150659A (es) 2016-01-29
PT3008062T (pt) 2017-06-07
PH12015502746A1 (en) 2016-03-21
US9586958B2 (en) 2017-03-07
AP2015008898A0 (en) 2015-12-31
PL3008062T3 (pl) 2017-08-31
MX2015017119A (es) 2016-04-06
DOP2015000299A (es) 2016-03-15
HRP20170717T1 (hr) 2017-07-28
PE20160156A1 (es) 2016-04-20
IL242847A0 (en) 2016-02-01
KR20160019492A (ko) 2016-02-19
SI3008062T1 (sl) 2017-06-30
CN105377848A (zh) 2016-03-02
UY35610A (es) 2015-01-30
HUE033131T2 (en) 2017-11-28
AU2014280356A1 (en) 2015-12-24
MA38654B1 (fr) 2018-11-30
EP3008062B1 (en) 2017-04-05
JP2016526534A (ja) 2016-09-05

Similar Documents

Publication Publication Date Title
SV2018005610A (es) Derivados de oxopiridina sustituidos
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
DOP2015000274A (es) Compuestos químicos
CL2015003686A1 (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
CL2016001895A1 (es) Compuestos
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2016003214A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
CL2016001151A1 (es) Derivados de purina 2,6-sustituidos y su uso en el tratamiento de trastorno proliferativos.
NI201500115A (es) Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CU20150176A7 (es) Derivados de prodroga de triazolpiridinas sustituídas
CR20160494A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
NI201700072A (es) Compuestos para tratar el cáncer.
DOP2015000290A (es) Benzoxazoles sustituidos